文献速递慢性肾脏病肾血管病与高血压

氨甲酰化作为慢性肾脏病患者冠状动脉钙化的新标志物:CRIC队列的全表型关联研究

Carbamylation as a Novel Marker of Coronary Artery Calcification in People With Chronic Kidney Disease: Findings from a Phenome-Wide Association Study in CRIC.
PubMed 文献 · Am J Kidney Dis · 2026-09-21

在3111例CRIC队列CKD患者中,以氨甲酰化白蛋白(C-Alb)评估氨甲酰化负荷,全表型关联分析发现47个显著关联,其中冠状动脉钙化关联最强。横断面分析显示C-Alb每升高1个标准差,CAC严重程度增加41%;纵向分析提示C-Alb与CAC进展相关。

要点

  • C-Alb与CAC患病率、严重程度及进展独立相关。
  • 氨甲酰化负荷与多种CKD相关临床表型广泛关联。
  • 氨甲酰化可能是CKD心血管风险的可干预靶点。

核心结论

  • 在CKD患者中,氨甲酰化与广泛临床表型相关,尤其心血管表型;C-Alb可能是CAC的独立危险因素。

研究设计与样本

  • 观察性队列研究,纳入CRIC队列3111例参与者,以C-Alb评估氨甲酰化负荷。

主要发现

  • 在212个表型中,多变量校正后C-Alb与47个临床表型显著关联。
  • 1046例接受CAC评估者中,CAC患病率为65%,最高C-Alb四分位组患病率最高。
  • 对数转换C-Alb每升高1个标准差,CAC严重程度增加41%。
  • 基线CAC为0的269例中55例出现新发CAC;基线CAC>0的389例中147例年进展≥50单位。
  • 多变量模型校正传统危险因素后,C-Alb与CAC进展相关。

临床怎么用

  • C-Alb或可用于CKD患者心血管钙化风险评估,但尚需外部验证。

局限性

  • 观察性设计可能存在残余混杂。
  • 新发CAC分析统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Protein carbamylation, a urea-driven posttranslational protein modification that increases in chronic kidney disease (CKD), affects diverse mechanisms relevant to the excess morbidity and mortality observed in this population. Given urea's ubiquitous presence in the body, we hypothesized that carbamylation would associate with a broad range of clinical phenotypes, specifically cardiovascular diseases. STUDY DESIGN: Observational cohort study. SETTINGS & PARTICIPANTS: 3,111 participants from the CRIC (Chronic Renal Insufficiency Cohort). EXPOSURE: Carbamylation burden assessed by carbamylated albumin (C-Alb). OUTCOME: Clinical phenotypes and coronary artery calcification (CAC) prevalence, severity, and progression. ANALYTICAL APPROACH: A phenome-wide association study evaluated associations between C-Alb and clinical phenotypes. Post-phenome-wide association study analyses examined the association of carbamylation with CAC measured by Agatston and total volume scores. RESULTS: Across 212 phenotypes, multivariable adjusted comparisons identified 47 significant associations between C-Alb and clinical phenotypes after accounting for multiple testing. Serum urea nitrogen showed one of the greatest associations. Among the most significant continuous phenotypes correlated with C-Alb, those within the coronary calcification category exhibited the greatest magnitude of association, prompting additional analysis. A total of 1,046 participants had CAC assessments (median age, 60 years; 46% female; median estimated glomerular filtration rate, 43 mL/min/1.73 m2), with CAC present in 65% and the highest C-Alb quartile showing the greatest prevalence. Cross-sectional analysis revealed that each 1-standard deviation increase in log-transformed C-Alb was associated with 41% greater CAC severity. Longitudinally, among 269 participants with a baseline CAC score of 0, 55 experienced incident CAC, whereas, among 389 with a baseline CAC score greater than 0, 147 showed an annual CAC progression of at least 50 units. C-Alb was associated with progressive CAC in multivariable models adjusting for traditional risk factors. LIMITATIONS: Observational design, residual confounding, and limited power for incident CAC analyses. CONCLUSIONS: Among patients with CKD, our findings showcase a wide range of phenotypic associations with carbamylation, particularly cardiovascular phenotypes. Carbamylation may be an independent risk factor for CAC, suggesting its potential as a therapeutic target to mitigate cardiovascular risk in CKD populations. PLAIN-LANGUAGE SUMMARY: People with chronic kidney disease (CKD) face an increased risk of cardiovascular disease, but the biological drivers of this risk are not fully understood. We studied protein carbamylation, a chemical process that increases as kidney function declines and urea accumulates in the body. In a large CKD cohort, higher carbamylation levels were strongly associated with coronary artery calcification measures, including greater severity and progression over time. Carbamylation was also linked to several other CKD-related health conditions. These findings suggest that carbamylation may play an important role in cardiovascular disease in CKD and could become a target for future therapies.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Awwad A, Garimella P, Rhee EP, et al. Carbamylation as a Novel Marker of Coronary Artery Calcification in People With Chronic Kidney Disease: Findings from a Phenome-Wide Association Study in CRIC. Am J Kidney Dis. 2026. PMID: 42767322. doi:10.1053/j.ajkd.2026.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。